Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

@article{Klement2002DifferencesIT,
  title={Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.},
  author={Giannoula Klement and Ping Huang and Barbara Mayer and Shane K. Green and S. E. P. Man and Peter Bohlen and Daniel J. Hicklin and Robert S. Kerbel},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2002},
  volume={8 1},
  pages={221-32}
}
One of the greatest barriers to the treatment of cancer with chemotherapeutic drugs is acquisition of drug resistance. This includes multidrug resistance mediated by P-glycoprotein (Pgp) to multiple lipophilic natural compounds such as taxanes, doxorubicin (Adriamycin), and vinblastine. The considerable efforts made thus far to reverse this and other types… CONTINUE READING